Richard Graham, PhD

Richard Graham, PhD, is chairman and co-founder of TruTechnologies. A clinical pharmacologist by training, Rick brings more than 25 years of drug development experience across oncology, immunology and inflammation, neuroscience, and respiratory disease. He has helped advance multiple therapeutics through late-stage development, contributing to approvals for Erivedge™, Kadcyla™, Kyprolis™, Perjeta™, and Yupelri™. Those experiences shaped his conviction that sponsors need earlier visibility into clinical trial execution.

Rick also co-founded Mirador Therapeutics, helping secure more than $400M in early-stage financing for its precision medicine platform targeting immune-mediated inflammatory and fibrotic diseases.